ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million
July 16, 2020I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors has authorized a stock repurchase program under
Pharma Sources Insight January 2025
